Frank Rimerman Advisors’s Procept Biorobotics PRCT Stock Holding History

Frank Rimerman Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.78M	Buy	122,912 +830	+0.7%	+$20.8K	0.16%	106
2026 Q1	$3.05M	Sell	122,082 -400	-0.3%	-$11.3K	0.2%	84
2025 Q4	$3.85M	Buy	122,482 +93	+0.1%	+$3.08K	0.24%	61
2025 Q3	$4.37M	Buy	122,389 +307	+0.3%	+$14K	0.28%	56
2025 Q2	$7.03M	Hold	122,082	–	–	0.47%	28
2025 Q1	$7.11M	Sell	122,082 -22	-0%	-$1.5K	0.56%	26
2024 Q4	$9.83M	Hold	122,104	–	–	0.71%	20
2024 Q3	$9.78M	Buy	122,104 +22	+0%	+$1.56K	0.69%	21
2024 Q2	$7.46M	Sell	122,082 -70,000	-36%	-$4.16M	0.53%	25
2024 Q1	$9.49M	Sell	192,082 -264,871	-58%	-$12.6M	1.83%	12
2023 Q4	$19.2M	Hold	456,953	–	–	4%	8
2023 Q3	$15M	Hold	456,953	–	–	3.63%	8
2023 Q2	$16.2M	Hold	456,953	–	–	3.86%	7
2023 Q1	$13M	Sell	456,953 -75,860	-14%	-$2.68M	3.59%	6
2022 Q4	$22.1M	Sell	532,813 -40,835	-7%	-$1.75M	6.89%	5
2022 Q3	$23.8M	Sell	573,648 -237,975	-29%	-$9.49M	8.58%	2
2022 Q2	$26.5M	Buy	+811,623	New	+$29.5M	10.13%	2

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Frank Rimerman Advisors's PRCT Position: Q2 2026 in Review

Frank Rimerman Advisors increased its Procept Biorobotics (PRCT) stake by 0.68% in Q2 2026, buying an estimated $20.8K and bringing the position to 122,912 shares worth $2.78M. The position accounts for 0.16% of the portfolio, ranked #106.

Frank Rimerman Advisors first reported a position in PRCT in Q2 2022 and has held it in 17 quarters since. The position peaked at $26.5M in Q2 2022. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

Frank Rimerman Advisors held 122,912 shares of Procept Biorobotics worth $2.78M as of Q2 2026.
Frank Rimerman Advisors bought 830 Procept Biorobotics shares in Q2 2026, an estimated $20.8K.
Procept Biorobotics made up 0.16% of Frank Rimerman Advisors's portfolio in Q2 2026, its #106 holding.
Frank Rimerman Advisors first reported a position in Procept Biorobotics in Q2 2022 and has held it in 17 quarters since.
Frank Rimerman Advisors's Procept Biorobotics position peaked at $26.5M in Q2 2022.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.